MANNKIND CORP (MNKD)

US56400P7069 - Common Stock

4.53  -0.1 (-2.16%)

After market: 4.53 0 (0%)

Fundamental Rating

4

Taking everything into account, MNKD scores 4 out of 10 in our fundamental rating. MNKD was compared to 592 industry peers in the Biotechnology industry. MNKD has a medium profitability rating, but doesn't score so well on its financial health evaluation. MNKD is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!



4

1. Profitability

1.1 Basic Checks

In the past year MNKD has reported negative net income.
In the past year MNKD had a positive cash flow from operations.
In the past 5 years MNKD always reported negative net income.
MNKD had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

MNKD has a better Return On Assets (-2.53%) than 92.52% of its industry peers.
MNKD has a Return On Invested Capital of 2.26%. This is amongst the best in the industry. MNKD outperforms 94.90% of its industry peers.
Industry RankSector Rank
ROA -2.53%
ROE N/A
ROIC 2.26%
ROA(3y)-19.1%
ROA(5y)-33.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Operating Margin value of 5.34%, MNKD belongs to the best of the industry, outperforming 94.73% of the companies in the same industry.
MNKD's Gross Margin of 68.45% is amongst the best of the industry. MNKD outperforms 82.99% of its industry peers.
MNKD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 5.34%
PM (TTM) N/A
GM 68.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.96%
GM growth 5Y21.68%

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MNKD is destroying value.
Compared to 1 year ago, MNKD has more shares outstanding
Compared to 5 years ago, MNKD has more shares outstanding
MNKD has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -7.30, we must say that MNKD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MNKD (-7.30) is worse than 72.62% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.3
ROIC/WACC0.27
WACC8.45%

2.3 Liquidity

A Current Ratio of 3.59 indicates that MNKD has no problem at all paying its short term obligations.
MNKD has a worse Current ratio (3.59) than 60.37% of its industry peers.
MNKD has a Quick Ratio of 3.31. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
MNKD has a worse Quick ratio (3.31) than 62.93% of its industry peers.
Industry RankSector Rank
Current Ratio 3.59
Quick Ratio 3.31

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.29% over the past year.
MNKD shows a strong growth in Revenue. In the last year, the Revenue has grown by 99.37%.
The Revenue has been growing by 48.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)85.29%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q100%
Revenue 1Y (TTM)99.37%
Revenue growth 3Y45.12%
Revenue growth 5Y48.13%
Revenue growth Q2Q61.97%

3.2 Future

Based on estimates for the next years, MNKD will show a very strong growth in Earnings Per Share. The EPS will grow by 70.58% on average per year.
The Revenue is expected to grow by 20.60% on average over the next years. This is a very strong growth
EPS Next Y295.84%
EPS Next 2Y158.62%
EPS Next 3Y114.24%
EPS Next 5Y70.58%
Revenue Next Year29.12%
Revenue Next 2Y27.53%
Revenue Next 3Y25.32%
Revenue Next 5Y20.6%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MNKD. In the last year negative earnings were reported.
MNKD is valuated quite expensively with a Price/Forward Earnings ratio of 46.26.
Based on the Price/Forward Earnings ratio, MNKD is valued cheaply inside the industry as 94.56% of the companies are valued more expensively.
MNKD is valuated expensively when we compare the Price/Forward Earnings ratio to 22.79, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 46.26

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 94.39% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 93.54

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MNKD's earnings are expected to grow with 114.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y158.62%
EPS Next 3Y114.24%

0

5. Dividend

5.1 Amount

No dividends for MNKD!.
Industry RankSector Rank
Dividend Yield N/A

MANNKIND CORP

NASDAQ:MNKD (3/28/2024, 8:25:02 PM)

After market: 4.53 0 (0%)

4.53

-0.1 (-2.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.23B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 46.26
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.53%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM 5.34%
PM (TTM) N/A
GM 68.45%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.59
Quick Ratio 3.31
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)85.29%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y295.84%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)99.37%
Revenue growth 3Y45.12%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y